Washington: A new brain cancer vaccine, which uses material from patients` own tumours, holds promise of extending their lives by several months, show results of a multicentre phase-two clinical trial of the vaccine.The effectiveness of the vaccine was tested on more than 40 patients undergoing treatment at the University of California, San Francisco Comprehensive Cancer Centre, University Hospitals Case Medical Centre, Cleveland, and New York-Presbyterian Hospital, New York City.The patients suffered from recurrent glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumour that kills thousands of Americans every year.The trial found that the vaccine could extend survival of the patients by several months compared to 80 other patients who were treated at the same hospitals and received standard therapy. Several of the patients who had received the cancer vaccine have survived for more than a year, according to a university statement.
Narendra Modi`s 17-point agenda for the nation
Power outage looms large as coal stocks dry
Bangalore rape case: NHRC slaps notice on govt
Don`t take us for granted, NCP warns Congress